These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17965512)

  • 1. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension.
    Ikeda D; Tsujino I; Sakaue S; Ohira H; Itoh N; Kamigaki M; Ishimaru S; Atsumi T; Nishimura M
    Circ J; 2007 Nov; 71(11):1829-31. PubMed ID: 17965512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beraprost therapy for pulmonary arterial hypertension.
    Barst RJ; McGoon M; McLaughlin V; Tapson V; Rich S; Rubin L; Wasserman K; Oudiz R; Shapiro S; Robbins IM; Channick R; Badesch D; Rayburn BK; Flinchbaugh R; Sigman J; Arneson C; Jeffs R;
    J Am Coll Cardiol; 2003 Jun; 41(12):2119-25. PubMed ID: 12821234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension.
    Kunieda T; Nakanishi N; Matsubara H; Ohe T; Okano Y; Kondo H; Nishimura M; Shirato K; Tanabe N; Homma S; Yoshida S; Inokuma S; Kodama M; Koike T; Hishida H
    Int Heart J; 2009 Jul; 50(4):513-29. PubMed ID: 19609055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
    Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G;
    J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
    Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T
    J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for pulmonary hypertension: striving for efficacy and safety.
    Kao PN; Faul JL
    J Am Coll Cardiol; 2003 Jun; 41(12):2126-9. PubMed ID: 12821235
    [No Abstract]   [Full Text] [Related]  

  • 7. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue.
    Vizza CD; Sciomer S; Morelli S; Lavalle C; Di Marzio P; Padovani D; Badagliacca R; Vestri AR; Naeije R; Fedele F
    Heart; 2001 Dec; 86(6):661-5. PubMed ID: 11711462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue.
    Sakao S; Tanabe N; Kasahara Y; Tatsumi K
    Intern Med; 2014; 53(17):1913-20. PubMed ID: 25175122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial hemodynamic effects of oral prostacyclin (PGI2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension--a case report.
    Hashida H; Hamada M; Shigematsu Y; Ikeda S; Kuwahara T; Kawakami H; Hara Y; Kodama K; Kohara K; Hiwada K
    Angiology; 1998 Feb; 49(2):161-4. PubMed ID: 9482517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension.
    Ikeda D; Tsujino I; Ohira H; Itoh N; Kamigaki M; Ishimaru S; Sakaue S; Nishimura M
    J Cardiovasc Pharmacol; 2005 Apr; 45(4):286-9. PubMed ID: 15772514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension.
    Ono F; Nagaya N; Kyotani S; Oya H; Nakanishi N; Miyatake K
    Circ J; 2003 May; 67(5):375-8. PubMed ID: 12736472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.
    Koyama A; Fujita T; Gejyo F; Origasa H; Isono M; Kurumatani H; Okada K; Kanoh H; Kiriyama T; Yamada S
    BMC Nephrol; 2015 Oct; 16():165. PubMed ID: 26475266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study.
    Vizza CD; Badagliacca R; Sciomer S; Poscia R; Battagliese A; Schina M; Agati L; Fedele F
    Cardiology; 2006; 106(3):168-73. PubMed ID: 16645271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of beraprost on pulmonary hypertension due to left ventricular systolic dysfunction.
    Wang L; Zhu X; Zhao LP; Wang M; Liu X; Chen Y; Chen J; Xu W
    Medicine (Baltimore); 2019 Apr; 98(16):e14965. PubMed ID: 31008926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results.
    Nakamoto H; Yu XQ; Kim S; Origasa H; Zheng H; Chen J; Joo KW; Sritippayawan S; Chen Q; Chen HC; Tsubakihara Y; Tamai H; Song SH; Vaithilingam I; Lee KW; Shu KH; Hok-King Lo S; Isono M; Kurumatani H; Okada K; Kanoh H; Kiriyama T; Yamada S; Fujita T
    Ther Apher Dial; 2020 Feb; 24(1):42-55. PubMed ID: 31119846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.